Download PDF
Clin Colon Rectal Surg 2001; 14(2): 167-174
DOI: 10.1055/s-2001-15855
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Medical Treatment of Crohn's Disease

Aaron Brzezinski
  • Department of Gastroenterology, The Cleveland Clinic, Cleveland, OH
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Medical treatment of Crohn's disease has progressed from empiric pharmaceuticals to biological agents. These medications help induce and maintain remission, prevent postoperative recurrence, improve quality of life, and suppress intestinal inflammation. A multidisciplinary team composed of surgeons, physicians, enterostomal therapists, and dietitians optimizes therapy and helps to minimize complications.

KEYWORD

Crohn's disease - medical treatment - corticosteroids

REFERENCES

  • 1 Azad Khan K A, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine.  Lancet . 1977;  2 892-895
    PubMedGoogle Scholar
  • 2 Thomson A BR, Wright J P, Vatn M. Mesalazine (Mesasal/Claversal) 1.5 g b.d. versus placebo in the maintenance of remission of patients with Crohn's disease.  Aliment Pharmacol Ther . 1995;  9 673-683
    PubMedGoogle Scholar
  • 3 McLeod R S, Wolff B G, Steinhart A H. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.  Gastroenterology . 1995;  109 404-413
    PubMedGoogle Scholar
  • 4 Camma C, Giunta M, Rosselli M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.  Gastroenterology . 1997;  113 1465-1473
    CrossrefPubMedGoogle Scholar
  • 5 Lochs H, Mayer M, Fleig W E. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI.  Gastroenterology . 2000;  118 264-273
    CrossrefPubMedGoogle Scholar
  • 6 Summers R W, Swit D M, Session J T. National Cooperative Crohn's Disease Study: results of drug treatment.  Gastroenterology . 1979;  77 847-869
    PubMedGoogle Scholar
  • 7 Malchow H, Ewe K, Brandes J W, Goebell H, Ehms H. European cooperative Crohn's disease study (ECCDS): results of drug treatment.  Gastroenterology . 1984;  86 249-266
    PubMedGoogle Scholar
  • 8 Singleton J W, Hanauer S B, Gitnick G L, Peppercorn M A, Robinson M G. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial.  Gastroenterology . 1993;  104 1293-1301
    PubMedGoogle Scholar
  • 9 Hanauer S B, Krawitt E L, Robinson M, Rick G G, Safdi M A. Long-term management of Crohn's disease with mesalamine capsules (Pentasa).  Am J Gastroenterol . 1993;  88 1343-1351
    PubMedGoogle Scholar
  • 10 Ursing B, Alm T, Barany F. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden.  Gastroenterology . 1982;  83 550-562
    PubMedGoogle Scholar
  • 11 Prantera C, Zannoni F, Scribano M L. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.  Am J Gastroenterol . 1996;  91 328-332
    PubMedGoogle Scholar
  • 12 Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.  Gastroenterology . 1995;  108 1617-1621
    CrossrefPubMedGoogle Scholar
  • 13 Colombel J F, Lemann M, Cassagnon M. GETAID: a controlled trial comparing ciprofloxacin and mesalazine for the treatment of active Crohn's disease.  Gastroenterology . 1997;  112 A951
    PubMedGoogle Scholar
  • 14 Giu G PH, Thomas P RS, Tizard M LV, Sanderson J D, Hermon-Taylor J. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics.  J Antimicrob Chemother . 1997;  39 393-400
    CrossrefPubMedGoogle Scholar
  • 15 Summers R W, Switz D M, Sessions Jr T J. National cooperative Crohn's disease study: results of drug treatment.  Gastroenterology . 1979;  77 847-869
    PubMedGoogle Scholar
  • 16 Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease.  Gut . 1994;  35 360-362
    CrossrefPubMedGoogle Scholar
  • 17 Rutgeerts P, Lofberg R, Malchow H. A comparison of budesonide with prednisolone for active Crohn's disease.  N Engl J Med . 1994;  331 842-845
    CrossrefPubMedGoogle Scholar
  • 18 Feagan B, Greenberg G R, Lofberg R. Budesonide controlled release ileal release prolongs remission in Crohn's disease: a pooled analysis.  Gastroenterology . 1997;  112 A970
    PubMedGoogle Scholar
  • 19 Hellers G, Cortot A, Jewell D. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease.  Gastroenterology . 1999;  116 294-300
    PubMedGoogle Scholar
  • 20 Schoon E J, Blok B M, Geerling B J. Bone mineral density in patients with recently diagnosed inflammatory bowel disease.  Gastroenterology . 2000;  119 1203-1208
    PubMedGoogle Scholar
  • 21 Hanauer S, Meyers S. Management of Crohn's disease in adults.  Am J Gastroenterol . 1997;  92 559-566
    PubMedGoogle Scholar
  • 22 Present D, Korelitz B I, Wisch N. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized double blind study.  N Engl J Med . 1980;  302 981-987
    CrossrefPubMedGoogle Scholar
  • 23 Markowitz J, Grancher K, Kohn N. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.  Gastroenterology . 2000;  119 895-902
    CrossrefPubMedGoogle Scholar
  • 24 Connell W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J L, Lennard-Jones J E. Safety of low-dose purine analogues in inflammatory bowel disease.  Gastroenterology . 1994;  107 1905-1906
    PubMedGoogle Scholar
  • 25 Lewis J D, Sanford Schwartz J, Lichtenstein G R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma.  Gastroenterology . 2000;  118 1018-1024
    CrossrefPubMedGoogle Scholar
  • 26 Duchesne D, Latours S, Leclerc J M, Sallan S E, Theoret Y. Pharmacokinetics of oral and intravenous 6-mercaptopurine (6-MP) in childhood acute lymphoblastic leukemia (ALL).  Proc Am Soc Clin Oncol . 1994;  13 A341
    PubMedGoogle Scholar
  • 27 Otterness D, Szumlanski C, Lennard L. Human thiopurine methyl-transferase pharmacogenetics: gene sequence polymorphisms.  Clin Pharmacol Ther . 1997;  62 60-73
    CrossrefPubMedGoogle Scholar
  • 28 Weinshilboum R M, Sladek S L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.  Am J Hum Genet . 1980;  32 651-662
    PubMedGoogle Scholar
  • 29 Dubinsky M C, Lamothe S, Yang H Y. Optimizing and individualizing 6-MP therapy in IBD: the role of 6-MP metabolite levels and TPMT genotyping.  Gastroenterology . 1990;  116 A702
    PubMedGoogle Scholar
  • 30 Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.  Gut . 1996;  39 401-406
    PubMedGoogle Scholar
  • 31 Cuffari C, Picco M, Hunt S. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD.  Gastroenterology . 1999;  116 A694
    PubMedGoogle Scholar
  • 32 Dubinsky M C, Lamothe S, Yang H Y. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.  Gastroenterology . 2000;  118 705-713
    CrossrefPubMedGoogle Scholar
  • 33 Achkar J P, Stevens T, Brzezinski A. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy (abstract).  Am J Gastroenterol . 2000;  96 2491
    PubMedGoogle Scholar
  • 34 Feagan B G, Rochon J, Fedorak R N. Methotrexate for the treatment of Crohn's disease.  N Engl J Med . 1995;  332 292-297
    CrossrefPubMedGoogle Scholar
  • 35 Feagan B G, Fedorak R N, Irvine E J. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease.  N Engl J Med . 2000;  342 1627-1632
    CrossrefPubMedGoogle Scholar
  • 36 Van Dullemen M H, Van Deventer J H S, Hommes D W, Bijl H A, Jansen J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).  Gastroenterology . 1995;  109 129-135
    PubMedGoogle Scholar
  • 37 Targan S R, Hanauer S B, Sander H H. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.  N Engl J Med . 1997;  337 1029-1035
    CrossrefPubMedGoogle Scholar
  • 38 Present D H, Rutgeerts P, Targan S. Infliximab treatment of fistulas in patients with Crohn's disease.  N Engl J Med . 1999;  340 1398-1405
    CrossrefPubMedGoogle Scholar
  • 39 Rutgeerts P, D'Haens G, Targan S. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.  Gastroenterology . 1999;  117 761-769
    CrossrefPubMedGoogle Scholar
  • 40 Hanauer S B, Cohen R D, Becker R V. Advances in the management of Crohn's disease: economic and clinical potential of infliximab.  Clin Ther . 1998;  20 1009-1028
    CrossrefPubMedGoogle Scholar
  • 41 Mate J, Castanos R, Garcia-Samaniego J, Pajares J M. Does dietary fish oil maintain remission of Crohn's disease: a study case control.  Gastroenterology . 1991;  100 A228
    PubMedGoogle Scholar
  • 42 Beluzzi A, Brignola C, Campieri M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease.  N Engl J Med . 1996;  334 1557-1560
    CrossrefPubMedGoogle Scholar
  • 43 Gonzalez-Huix F, de Leon R, Fernandez-Banares F. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.  Gut . 1993;  34 778-782
    PubMedGoogle Scholar
  • 44 Sampaio E P, Kaplan G, Miranda A. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.  J Infect Dis . 1993;  168 408-414
    CrossrefPubMedGoogle Scholar
  • 45 Ehrenpreis E D, Kane S K, Cohen L B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.  Gastroenterology . 1999;  117 1271-1277
    PubMedGoogle Scholar
  • 46 Vasiliauskas E A, Kam L Y, Abreu-Martin M T. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.  Gastroenterology . 1999;  117 1278-1287
    PubMedGoogle Scholar
  • 47 Zeldis J B, Williams B A, Thomas S D. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide.  Clin Ther . 1999;  21 319-330
    CrossrefPubMedGoogle Scholar